Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | DRD4 | P21917 | 5/20 | 0.78 |
| ▸ | DRD2 | P14416 | 4/20 | 0.74 |
| ▸ | DRD3 | P35462 | 3/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.74 |
| ▸ | HTR7 | P34969 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HRH2 | P25021 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031726 | 0.90 | MAPK1 (0.80) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL6031061 | 0.90 | MAPK1 (0.80) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL18177886 | 0.90 | MAPK1 (1.00) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL19561754 | 0.90 | MAPK1 (0.80) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL9720681 | 0.88 | MAPK1 (0.78) | MAPK1DRD4DRD2DRD3HTR7 | |
| Bromide SCHEMBL6575673 | 0.88 | MAPK1 (0.78) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL7790707 | 0.88 | SLC6A2 (0.66) | MAPK1DRD4DRD2DRD3ADRA1D | |
| SCHEMBL7991732 | 0.88 | DRD4 (1.00) | MAPK1DRD4DRD2DRD3ADRA1D | |
| SCHEMBL8744973 | 0.87 | MAPK1 (0.70) | MAPK1DRD4DRD2DRD3HTR7 | |
| SCHEMBL13030891 | 0.87 | DRD4 (0.72) | MAPK1DRD4DRD2DRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576520-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| CN-102216282-A | Aryl piperazines and their use as alpha 2C antagonists | ORION CORP | 2011-10-12 | — | — | CN | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | disclosed |
| EP-0650964-A1 | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1995-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | MAPK1 918/4885DRD4 301/4885DRD2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.